SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Anesiva, Inc. announced today that John P. McLaughlin, the company's chief executive officer, will present at the C.E. Unterberg, Towbin Life Sciences Conference on October 30, 2006 at 3:30 pm EST in New York City.
To access the live webcast or the subsequent archived recording, log on to www.anesiva.com and go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The related slides will be posted to the Anesiva website and may be accessed on October 30, 2006.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications, the most advanced of which, Zingo(TM), has completed Phase 3 clinical trials. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site- specific, moderate-to-severe pain. A third product, 1207, is currently being evaluated in a Phase 1 clinical trial as a topical local anesthetic. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com .
Anesiva, Inc.CONTACT: Jennifer Cook Williams, Vice President, Investor Relations ofAnesiva, +1-650-624-9600, or investors@anesiva.com
Web site: http://www.anesiva.com//
